Drug Database
LO

losartan + HCTZ (Gizaar / Hyzaar / Cozaar plus)

✓ Approved

Merck & Co. · AGTR1 · 小分子

什么是 losartan + HCTZ?

losartan + HCTZ 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Gizaar, Hyzaar, Cozaar plus
公司Merck & Co.
药物类别小分子
分子靶点AGTR1, SLC12A3
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

losartan + HCTZ 作用于 2 个分子靶点:

AGTR1angiotensin II receptor type 1 (HAT1R, AT1)
SLC12A3solute carrier family 12 member 3 (NCCT, NCC)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

losartan + HCTZ 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedBreastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine2026-11-18

Association Between Pregnant Women's Views on Breast Milk Substitutes and Infant Feeding Attitudes.

Köken Durgun Seçil S, Cambaz Ulaş Seval S

This study aimed to examine the impact of pregnant women's perceptions of breast milk substitutes (BMS) on their attitudes toward breastfeeding. This cross-sectional study was conducted at the Obstetrics and Gynecology Outpatient Clinic of a state hospital in Türkiye between September 2024 and June 2025. The sample included 379 pregnant women who met the inclusion criteria and agreed to participate. Data were collected using the "Pregnancy Information Form" and the "Iowa Infant Feeding Attitude Scale (IIFAS)." For half of the participants, this was their first pregnancy. Among women with living children, 92.1% had a history of breastfeeding. The mean total IIFAS score was 61.21 ± 7.43. Multiple regression analysis showed that a history of infant formula use (β = -0.177, p = 0.037), intention to try BMS (β = -0.223, p = 0.004), and belief that BMS pose a health risk to the infant (β = 0.205, p = 0.006) significantly influenced infant feeding attitudes. The vast majority of participants perceived advertisements for BMS as encouraging their use. Attitudes toward breastfeeding were particularly influenced by past infant formula use and marketing exposure. However, those who recognized the health risks of substitutes demonstrated more favorable breastfeeding attitudes.

PMID 43046829
阅读全文 →
PubMedJournal of orthopaedic surgery and research2026-11-18

Bone marrow stimulation in arthroscopic rotator cuff repair: a meta-analysis.

Cerciello Simone S, Mocini Fabrizio F, Cofano Erminia E, Mattiacci Vincenzo V et al.

Arthroscopic rotator cuff repair (ARCR) is a common and successful operation; however, re-ruptures are relatively common. The association of Bone marrow stimulation (BMS) has been proposed to increase outcomes and reduce re-tear rates. The study aims to compare the effect of concomitant BMS and ARCR with isolated rotator cuff repair (RCR). The PubMed, MEDLINE, Scopus, and Cochrane Central databases were used to search for keywords, and a total of 15 studies were included. The primary outcomes were retear rates. The data extracted for quantitative analysis include the American Shoulder and Elbow Surgeons (ASES), Constant-Murley score (CMS), University of California, Los Angeles (UCLA) scores, simple shoulder test (SST), visual analogue scale (VAS), and range of motion. A total of 2193 relevant articles were identified, and 15 comparative studies were eligible for the meta-analysis. A total of 1552 patients were identified, of whom 776 and 776 underwent ARCR with BMS stimulation and isolated ARCR, respectively. At FU, a significantly higher retear rate was observed in the isolated ARCR group (14% vs 18%, OR = 0.69, 95% CI [0.51, 0.92], P = 0.01). When only patients with double-row were considered, no significant difference was found between the groups (11% vs 16%, OR = 0.66, 95% CI [0.42,1.04], P = 0.07); however, when only patients with single-row were analyzed, an even more significantly higher retear rate was found in the isolated ARCR group (16% vs 27%, OR = 0.42,95% CI [0.26, 0.66], P = 0.0002). A statistically significant difference was found in favor of the ARCR with the BMS group in terms of elevation, while no difference was found in terms of external and internal rotation. This meta-analysis showed significantly lower retear rate in the ARCR with BMS group, especially for those patients who received single row repair, with significantly superior outcomes in terms of ASES, CMS, and elevation at last FU. No statistically significant difference was observed in retear rate in patients who received double-row repair, in terms of SST, UCLA score, VAS, external and internal rotation at last FU. III.

PMID 43046091
阅读全文 →
PubMedAnalytical chemistry2026-11-18

MALDI-TOF Mass Spectrometry Imaging for Spatially Resolved Degradation Profiling of Solid Formulations.

Thomas Rekha R, Vargas Karina A KA, Shi Zhenqi Z, Gruenhagen Jason J et al.

Understanding the stability of the active pharmaceutical ingredient (API) and drug-excipient interactions is critical for ensuring the efficacy and shelf life of pharmaceutical formulations. This study applies matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) to investigate two-dimensional (2D) and three-dimensional (3D) spatial profiling of degradants in Losartan potassium tablets that are subjected to temperature- and humidity-induced stress conditions. This approach allows for in situ visualization of API degradation and excipient compatibility within solid dosage forms. Upon stress, Losartan tablets formed dimeric and trimeric species as major degradation products. Spatial mapping revealed a gradual growth of these degradants from the control (T0) through four weeks of stress. Ion images showed distinct heterogeneity in the formation of dimer and trimer species across the tablet depth and plane; however, no preferential pattern was observed at the tablet periphery. The random distribution of degradants suggests that alongside humidity, localized microenvironments drive the degradation process. MALDI-MSI demonstrates strong potential as a high-throughput and sensitive alternative to traditional liquid chromatography-based procedures for early-stage formulation screening. Furthermore, this work suggests that when integrated with orthogonal techniques to coregister excipient domains, MALDI-MSI can serve as an emerging tool to uniquely characterize drug-excipient interactions during early-stage drug development. This provides spatially resolved insight that enhances accelerated stability assessment programs and streamline the selection of compatible excipients.

PMID 43046425
阅读全文 →
PubMedJournal of clinical medicine2026-11-14

Restless Head Syndrome and Burning Mouth Syndrome: Clinical Overlap and Diagnostic Pitfalls in Orofacial Pain.

Obermeier Katharina Theresa KT, Abdullah Anusha A, Kramer Felix F, Dewenter Ina I et al.

Restless Head Syndrome (RHS) and Burning Mouth Syndrome (BMS) are rare, underrecognized causes of orofacial discomfort that are frequently misdiagnosed. This review maps the available literature on both conditions, examines their proposed relationship to restless leg syndrome (RLS) and to each other, and appraises the role of dopaminergic therapy. A literature search was conducted in PubMed and ScienceDirect for publications from January 2000 to December 2024 describing the clinical presentation, diagnosis, or treatment of RHS, BMS, or craniofacial variants of RLS. The evidence consisted predominantly of case reports and small case series. RHS and other craniofacial RLS variants presented with rest-associated, evening-predominant discomfort that was relieved by movement and responded to dopaminergic agents. Only one small case series described patients with BMS who also fulfilled RLS criteria. The evidence supports clinical similarities rather than a confirmed association or shared pathophysiology. Clinicians should consider atypical RLS variants in the differential diagnosis of unexplained orofacial sensory symptoms; prospective studies are needed before firm diagnostic or therapeutic conclusions can be drawn.

PMID 43030718
阅读全文 →
PubMedMolecules (Basel, Switzerland)2026-11-14

Phenylpropanoid Amides from Buteae monospermae Semen as Hepcidin-Modulating Candidates for Anemia of Inflammation: Network Pharmacology, Deep Learning Prediction, and In Vitro Validation.

Li Hongfang H, Zhang Qin Q, Xia Liyan L, Ding Xiaolin X et al.

Anemia of inflammation (AI) is largely driven by interleukin-6 (IL-6)-induced hepcidin overproduction, which disrupts systemic iron homeostasis. Buteae monospermae Semen (BMS), the seeds of Butea monosperma (Lam.) Kuntze and a traditional Tibetan medicine, has long been used for blood-related disorders, yet its active constituents against AI remain unclear. Here, an integrated strategy combining ADMET screening, network pharmacology, deep learning-based affinity prediction, molecular docking, molecular dynamics simulation, and in vitro validation was applied to 58 BMS-derived compounds. Forty-three candidates with acceptable ADMET profiles were retained, and their predicted targets were enriched in inflammation- and iron metabolism-related pathways, particularly IL-6/JAK2/STAT3 signaling. Two phenylpropanoid amides, compounds 16 and 21, were prioritized and shown to interact favorably with hepcidin-related regulatory targets. In IL-6-stimulated HepG2 cells, both compounds dose-dependently reduced hepcidin levels (EC50 = 2.486 and 14.49 μM), with therapeutic indices of 4.40 and 33.7, respectively. These findings identify BMS-derived phenylpropanoid amides as hepcidin-modulating candidates for AI and demonstrate an effective computational-experimental strategy for discovering bioactive compounds from traditional medicines.

PMID 43029342
阅读全文 →
PubMedCancers2026-11-14

Representation of Surgery in Registered Clinical Trials for Brain Metastases: An Analysis of the ClinicalTrials.gov Database.

Leskinen Sandra S, Shlobin Nathan A NA, Scott Roland A RA, Haile Hannah H et al.

Background/Objectives: Brain metastases (BMs) represent a significant clinical challenge affecting 10-26% of patients who die from cancer. While surgery plays an established role in the management of selected patients, its representation within the registered clinical trial landscape has not been systematically characterized. Methods: In this cross-sectional registry analysis, ClinicalTrials.gov was searched on 20 December 2025, using condition terms related to BMs combined with the Boolean operator OR. Interventional and observational studies were included without restrictions on phase, status, sex, or age; trials not updated since 1 January 2015 were excluded. Included studies were classified as surgery-focused, surgery-enabled, or non-surgical. Data were extracted on study characteristics, interventions, and outcomes. Results: A total of 493 trials were included. Of these, 57 (11.6%) involved surgery, including 9 (1.8%) surgery-focused and 48 (9.7%) surgery-enabled trials, whereas 436 (88.4%) were non-surgical. Radiotherapy was the dominant treatment platform, present in 262 trials (53.1%), with stereotactic radiosurgery reported in 179 (36.3%). Among the 57 surgical trials, the most common primary endpoint categories were periprocedural/safety and local control outcomes (each 26/57, 45.6%) and survival (20/57, 35.1%). Only 4 surgical trials (7.0%), all surgery-focused, had a primary endpoint that directly measured an operative outcome. Conclusions: Surgery accounted for a minority of registered brain metastasis trials and more commonly served as context for evaluating adjuvant, radiation-based, and multimodality approaches than as the primary intervention under study. Surgical trials were weighted toward safety, local control, and survival endpoints, with less frequent emphasis on surgery-specific and functional outcomes.

PMID 43026828
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多losartan + HCTZ